ERYTHRODERMIC PSORIASIS

Clinical trials for ERYTHRODERMIC PSORIASIS explained in plain language.

Never miss a new study

Get alerted when new ERYTHRODERMIC PSORIASIS trials appear

Sign up with your email to follow new studies for ERYTHRODERMIC PSORIASIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

New drug TAK-279 targets rare, severe psoriasis in phase 3 trial

Disease control Completed

This phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-l…

Matched conditions: ERYTHRODERMIC PSORIASIS

Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control

Last updated Aug 01, 2026 00:00 UTC

ERYTHRODERMIC PSORIASIS

Get alerted when new ERYTHRODERMIC PSORIASIS trials appear

New drug TAK-279 targets rare, severe psoriasis in phase 3 trial